Image Credit: STAT News
STAT+: Pharmalittle: We’re reading about FDA drug reviews, Novartis investing $23 billion in the U.S., and more
While FDA drug and device reviewers and inspectors were protected from layoffs, drug reviews are likely to be affected, anyway